Modulation of anxiety through blockade of anandamide hydrolysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion. But the variable effects of Δ9-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists. An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation. Here we describe a class of potent, selective and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degradation of the endogenous cannabinoid anandamide. Like clinically used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations. These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade. Our results indicate that anandamide participates in the modulation of emotional states and point to fatty acid amide hydrolase inhibition as an innovative approach to anti-anxiety therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both serotonin and endocannabinoids are involved in stress-related phenotypes, such as anxiety (212).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“the endogenous cannabinoids, such as anandamide, sleep-inducing substance oleamide (211) and palmitoylethanolamide (212), regulate numerous biological processes such as neuronal migration (213), learning, memory (214), pain processing (215), motility (216), and emotional-and reward-related processing (217–219).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“Nabilone (Cesamet; Valeant Canada, Ltd., Montreal, Canada), an endocannabinoid receptor (CB 1 and CB 2 ) agonist, has been in use in Europe and Canada for over 25 years and was recently granted approval in the United States for the treatment of chemotherapy-induced nausea and vomiting.”
From The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD) (2009) · cites this paper as [12]
In the citing paper
“It has been well established that inhibition of FAAH, and elevation of AEA signaling, can significantly attenuate behavioral indices of fear and anxiety-related behavior in rodents.”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Kathuria et al., 2003
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationMechanisms of emotional arousal and lasting declarative memory.
Cahill, L., & McGaugh, J. L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01214-9 · Cited by 1,575
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Self-citationBrain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
Self-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Cited by
Items 601–700 of 1,002
Bassi, M. S., Gilio, L., Maffei, P., Dolcetti, E., Bruno, A., Buttari, F., Centonze, D., & Iezzi, E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00424 · Cited by 52
“In particular, it has been demonstrated that FAAH inhibitors reduced anxiety-like behavior in the elevated-zero maze and in the isolation-induced ultrasonic-emission tests (Kathuria et al., 2003).”
BackgroundPharmacological convergence reveals a lipid pathway that regulates C. elegans lifespan
Chen, A. L., Lum, K. M., Lara-González, P., Ogasawara, D., Cognetta, A. B., To, A., Parsons, W. H., Simon, G. M., Desai, A. B., Petrascheck, M., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0243-4 · Cited by 51
Cannabis and endocannabinoid modulators: Therapeutic promises and challenges
Grant, I., & Cahn, B. R. (2005) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2005.08.015 · Cited by 63
“One such effect, the ability to reduce anxiety-like behaviors in rats, was demonstrated in the elevated ‘zero maze’ test, and the isolation-induced ultrasonic emission test [125].”
Backgroundde Bruin, N. M. W. J., Lange, J. H. M., Kruse, C. G., Herremans, A. H. J., Schoffelmeer, A. N. M., Drimmelen, M. V., & Vries, T. J. D. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.013 · Cited by 53
The Endocannabinoid System: Current Pharmacological Research and Therapeutic Possibilities
Jonsson, K., Holt, S., & Fowler, C. J. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_376.x · Cited by 57
Lipases and their inhibitors in health and disease
Nomura, D. K., & Casida, J. E. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.04.004 · Cited by 53
Endogenous N -acyl taurines regulate skin wound healing
Sasso, O., Pontis, S., Armirotti, A., Cardinali, G., Kovacs, D., Migliore, M., Summa, M., Moreno‐Sanz, G., Picardo, M., & Piomelli, D. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1605578113 · Cited by 54
“Raw data from high-resolution LC-MS/MS runs for either polarity (ESI+ or ESI−) were subjected to Pareto-scaled PCA (16) by using the MarkerLynx software (Waters Inc.).”
BackgroundMethodInfluentialSelf-citationLomazzo, E., König, F., Abassi, L., Jelinek, R., & Lutz, B. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.10.008 · Cited by 52
FAAH inhibition as a preventive treatment for migraine: A pre-clinical study
Greco, R., Demartini, C., Zanaboni, A. M., Tumelero, E., Reggiani, A. M., Misto, A., Piomelli, D., & Tassorelli, C. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104624 · Cited by 51
“doing so, enhances the activity of this endocannabinoid lipid at CB1 receptors in the brain and peripheral tissues (Kathuria et al., 2003; Fegley et al., 2005).”
InfluentialSelf-citationGonçalves, E. C. D., de Assis, P. M., Junqueira, L. A., Cola, M., Santos, A. R. S., Raposo, N. R. B., & Dutra, R. C. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b01134 · Cited by 54
Chesterfield, A. K., Kidd, S. R., Moore, S. A., Schaus, J. M., Liu, B., Nomikos, G. G., & Felder, C. C. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9072-6 · Cited by 55
“5 nM) with no effect on anandamide uptake (Kathuria et al., 2003), data presented here suggest that not only does URB597 inhibit anandamide uptake, but it also inhibits binding to a site other than FAAH involved in anandamide uptake.”
BackgroundInfluentialGenetic Loss of Faah Compromises Male Fertility in Mice1
Sun, X., Wang, H., Okabe, M., Mackie, K., Kingsley, P. J., Marnett, L. J., Cravatt, B. F., & Dey, S. K. (2008) · Biology of Reproduction · doi:10.1095/biolreprod.108.072736 · Cited by 50
Global Portrait of Protein Targets of Metabolites of the Neurotoxic Compound BIA 10–2474
Huang, Z., Ogasawara, D., Seneviratne, U. I., Cognetta, A. B., Ende, C. W. A., Nason, D. M., Lapham, K., Litchfield, J., Johnson, D. S., & Cravatt, B. F. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b01097 · Cited by 52
Ezzili, C., Mileni, M., McGlinchey, N., Long, J. Z., Kinsey, S. G., Hochstatter, D. G., Stevens, R. C., Lichtman, A. H., Cravatt, B. F., Bilsky, E. J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101597x · Cited by 54
Potential Therapeutic Value of a Novel FAAH Inhibitor for the Treatment of Anxiety
Marco, E. M., Rapino, C., Caprioli, A., Borsini, F., Laviola, G., & Maccarrone, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137034 · Cited by 50
“URB597, AACOCF3 or PF-3845 [10,11], and have been associated with anxiolytic, antidepressant and analgesic properties in rodents [12,13,14].”
BackgroundMethodInfluentialZhou, Y., Schwartz, B. I., Giza, J. I., Gross, S. S., Lee, F. S., & Kreek, M. J. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4691-9 · Cited by 55
“Pharmacologic and genetic manipulations (knockout or knock-in) of FAAH have been implicated in anxiolytic and anti-depressive behaviors (Bortolato et al. 2007; Gunduz-Cinar et al. 2013; Kathuria et al. 2003; Moreira et al. 2008; Carnevali et al. 2015).”
Endocannabinoid regulation of relapse mechanisms
Fattore, L., Fadda, P., & Fratta, W. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.004 · Cited by 51
Manwell, L. A., Satvat, E., Lang, S. T., Allen, C. P., Leri, F., & Parker, L. A. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.08.002 · Cited by 48
Fetal Alcohol Spectrum Disorder: Potential Role of Endocannabinoids Signaling
Basavarajappa, B. S. (2015) · Brain Sciences · doi:10.3390/brainsci5040456 · Cited by 52
Ogawa, S., & Kunugi, H. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150612225212 · Cited by 51
“Several inhibitors of these enzymes are reported to have no cannabimimetic side effects [7-10].”
Nia, A. B., Bender, R. L., & Harpaz‐Rotem, I. (2019) · Chronic Stress · doi:10.1177/2470547019864096 · Cited by 52
“Evidence consistently shows that pharmacologic FAAH inhibition promotes fear extinction and reduces anxious behaviors in rodent models.(37,38) In humans, a loss of function allele resulting in reduced FAAH activity (and subsequent increased basal AEA levels) has also been shown to facilitate fear extinction and was as…”
BackgroundPonzano, S., Bertozzi, F., Mengatto, L., Dionisi, M., Armirotti, A., Romeo, E., Berteotti, A., Fiorelli, C., Tarozzo, G., Reggiani, A. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400739u · Cited by 54
Self-citationA human gut Faecalibacterium prausnitzii fatty acid amide hydrolase
Cheng, J., Venkatesh, S., Ke, K., Barratt, M. J., & Gordon, J. I. (2024) · Science · doi:10.1126/science.ado6828 · Cited by 53
Sakın, Y. S., Dogrul, A. B., İlkaya, F., Seyrek, M., Ulaş, Ü. H., Gülşen, M., & Bagci, S. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12563 · Cited by 51
Ivy, D. M., Palese, F., Vozella, V., Fotio, Y., Yalcin, A., Ramirez, G. L., Mears, D. J., Wynn, G. H., & Piomelli, D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0696-x · Cited by 50
“In both studies, CB1 receptor blockade completely prevented the effects of FAAH inhibition.”
BackgroundInfluentialSelf-citationThors, L., Eriksson, J. W., & Fowler, C. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707401 · Cited by 47
“FAAH has been well characterized, and selective inhibitors, such as (30(aminocarbamoyl)[1,10-biphenyl]-3-yl)-cyclohexylcarbamate (URB597) (Kathuria et al., 2003), are currently being used to explore the physiological importance of this enzyme.”
BackgroundMurillo‐Rodríguez, E., Palomero‐Rivero, M., Millán‐Aldaco, D., Arias-Carrión, Ó., & Drucker-Colín, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020766 · Cited by 50
Zaniewska, M., McCreary, A. C., Przegaliński, E., & Filip, M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.04.034 · Cited by 48
Varvel, S. A., Cravatt, B. F., Engram, A. E., & Lichtman, A. H. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.095059 · Cited by 49
“ABBREVIATIONS: FAAH, fatty acid amide hydrolase; FAA, fatty acid amide; OLE, 9-(Z)-octadecenamide (oleamide); PEA, N-palmitoylethanolamine; OEA, N-oleoylethanolamine; CB1, central cannabinoid receptor; SR141716, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)4-methyl-1H-pyrazole-3-carboxamide HCl; THC, 9-…”
BackgroundEffects of endocannabinoid neurotransmission modulators on brain stimulation reward
Vlachou, S., Nomikos, G. G., & Panagis, G. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0506-0 · Cited by 50
“1995); URB-597, an inhibitor of intracellular FAAH activity (Kathuria et al. 2003; Fegley et al. 2004, 2005) and OMDM-2, a selective and metabolically stable inhibitor of anandamide cellular uptake that has minimal activity against FAAH (Ortar et al.”
BackgroundInfluentialVandevoorde, S., & Fowler, C. J. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706253 · Cited by 48
Pharmacological activation of kainate receptors drives endocannabinoid mobilization
Lourenço, J., Matias, I., Marsicano, G., & Mulle, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3512-10.2011 · Cited by 46
“The inhibition of AEA degradation by the fatty acid amide hydrolase (FAAH) inhibitor URB597 [1 M (Kathuria et al., 2003)] significantly prolonged the effect of KA (two-way ANOVA, F(2,957) 8.65, p 0.001, drug time) (Fig.”
BackgroundInfluentialBiochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase
Thors, L., Burston, J. J., Alter, B. J., McKinney, M., Cravatt, B., Ross, R., Pertwee, R. G., th, R. W. G., Wiley, J. L., & Fowler, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00716.x · Cited by 48
“The small difference in the relative potencies of biochanin A and URB597 (as compared with the large difference in vitro, where URB597 inhibits FAAH in the low nanomolar range; Kathuria et al., 2003) may reflect the reduced local pH of the inflamed tissue (Häbler, 1929), because URB597 inhibits FAAH in intact cells in…”
BackgroundThe Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review
Fowler, C. J. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_4 · Cited by 46
Slusar, J. E., Cairns, E. A., Szczesniak, A.-M., Bradshaw, H. B., Polo, A. D., & Kelly, M. E. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.018 · Cited by 48
“Oakville, ON, Canada), in 1:3 ratio DMSO to saline (Kathuria et al., 2003), and”
BackgroundMethodSerum contents of endocannabinoids are correlated with blood pressure in depressed women
Ho, W. ‐. V., Hill, M. N., Miller, G. E., Gorzalka, B. B., & Hillard, C. J. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-32 · Cited by 48
“In this regard, it is interesting to note that inhibitors of fatty acid amide hydrolase have been proposed to reduce the symptoms of anxiety and depression [43,44].”
BackgroundModulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase
Haller, V. L., Stevens, D. L., & Welch, S. P. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.08.005 · Cited by 52
Vandevoorde, S., Saha, B., Mahadevan, A., Razdan, R. K., Pertwee, R. G., Martin, B. R., & Fowler, C. J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.015 · Cited by 48
Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain
Palkovits, M., Harvey-White, J., Liu, J., Kovács, Z., Bobest, M., Lovas, G., Bagó, A. G., & Kunos, G. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.01.034 · Cited by 46
Accumulation of anandamide: Evidence for cellular diversity
Hillard, C. J., & Jarrahian, A. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.12.012 · Cited by 46
“Similarly, FAAH inhibitors do not reduce the accumulation of AEA in astrocytes (Beltramo et al., 1997) or cortical neurons (Kathuria et al., 2003) in spite of the fact that these cells have FAAH activity.”
BackgroundJain, U., Soni, S., Balhara, Y. P. S., Khanuja, M., & Chauhan, N. (2020) · ACS Omega · doi:10.1021/acsomega.0c00285 · Cited by 45
“Other than this, the “ on demand ” production of AEA endocannabinoids and rapid clearance through cellular uptake followed by enzyme serine hydrolase fatty acid amide hydrolase (FAAH) metabolism 6,13,14 also make it valuable in the neural system of mammals.”
Wright, L. K. M., Liu, J., Nallapaneni, A., & Pope, C. (2009) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2009.12.006 · Cited by 48
“[23] reported that URB597, a FAAH inhibitor [13], elicited anxiolytic behavior in rats.”
BackgroundVacondio, F., Silva, C., Lodola, A., Fioni, A., Rivara, S., Duranti, A., Tontini, A., Sanchini, S., Clapper, J. R., Piomelli, D., et al. (2009) · ChemMedChem · doi:10.1002/cmdc.200900120 · Cited by 47
Self-citationGobira, P. H., Lima, I. V. D. A., Batista, L. A., de Oliveira, A. C., Resstel, L. B. M., Wotjak, C. T., de Aguiar, D. C., & Moreira, F. A. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117691567 · Cited by 48
“The FAAH inhibitor, URB597 (Cayman Chemical Company, Ann Arbor, MI, USA), was injected through the intraperitoneal route at the doses of 0.1, 0.3 and 1.0 mg/kg (Kathuria et al., 2003; Micale et al., 2009; Moreira et al., 2008).”
BackgroundMethodInfluentialSchlosburg, J. E., Kinsey, S. G., Ignatowska-Jankowska, B., Ramesh, D., Abdullah, R. A., Tao, Q., Booker, L., Long, J. Z., Selley, D. E., Cravatt, B. F., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.212753 · Cited by 44
“However, FAAH and MAGL inhibitors lack full efficacy in preclinical models of acute (Kathuria et al., 2003; Long et al., 2009a,c), neuropathic (Kinsey et al., 2009, 2010), and inflammatory (Alhouayek et al., 2011; Ghosh et al., 2013; Anderson et al., 2014) pain, though they appear fully efficacious…”
BackgroundMiller, L. L., Picker, M. J., Umberger, M. D., Schmidt, K. T., & Dykstra, L. A. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.191478 · Cited by 44
Stressed-out endogenous cannabinoids relieve pain
Vaughan, C. W. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.011 · Cited by 44
Thiemann, G., Watt, C. A., Ledent, C. A., Molleman, A., & Hasenöhrl, R. U. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.035 · Cited by 44
Lisboa, S. F. D. S., Borges, A. A., Nejo, P., Fassini, A., Guimarães, F. S., & Resstel, L. B. M. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.01.005 · Cited by 51
“The anxiolytic effects of AM404 or FAAH inhibitors systemically administrated are paralleled by increases in AEA concentrations in brain regions that include the PFC (Bortolato et al., 2006; Kathuria et al., 2003), indicating this structure could be involved in these effects.”
Palermo, G., Branduardi, D., Masetti, M., Lodola, A., Mor, M., Piomelli, D., Cavalli, A., & Vivo, M. D. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2004283 · Cited by 44
Self-citationPotent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies
Migliore, M., Habrant, D., Sasso, O., Albani, C., Bertozzi, S. M., Armirotti, A., Piomelli, D., & Scarpelli, R. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.036 · Cited by 44
“[51] This scaffold merges key pharmacophores of two known classes of FAAH and COX inhibitors – O-aryl carbamates [52-58] such as [3-(3-carbamoylphe nyl)phenyl] Ncyclohexylcarbamate (URB597, 2) [54, 57], and 2-aryl propionic acids [6] such as flurbiprofen, 3a [59-61] – which share a biphenyl core as a common structural…”
Self-citationDon, W., Lee, D., Li, D., Daglian, J. M., Jung, K., & Piomelli, D. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4222-0 · Cited by 47
“For example, pharmacological inhibition or genetic deletion of the enzyme that hydrolyzes anandamide, fatty acid amide hydrolase (FAAH), markedly increases anandamide activity at CB1 receptors (Cravatt et al. 2001; Kathuria et al. 2003).”
BackgroundSelf-citationEndocannabinoids and striatal function: implications for addiction-related behaviours
Moreira, F. A., Jupp, B., Belin, D., & Dalley, J. W. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000109 · Cited by 50
“…levels, appear to have more consistent effects on anxiety responses under highly aversive conditions, presumably because anandamide appears to be recruited as a protective mechanism in response to stress (Kathuria et al., 2003; Patel and Hillard, 2006; Naidu et al., 2007; Moreira et al., 2008).”
BackgroundColangeli, R., Morena, M., Pittman, Q. J., Hill, M. N., & Teskey, G. C. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.0068-20.2020 · Cited by 50
“The dose was chosen based on previous published papers (Kathuria et al., 2003) and on pilot experiments performed in our laboratory.”
BackgroundMethodVogel, A., Wilken‐Schmitz, A., Hummel, R., Lang, M., Gurke, R., Schreiber, Y., Schäfer, M. K. E., & Tegeder, I. (2020) · Scientific Reports · doi:10.1038/s41598-020-71879-x · Cited by 46
Greco, R., Demartini, C., Zanaboni, A., Casini, I., Icco, R. D., Reggiani, A. M., Misto, A., Piomelli, D., & Tassorelli, C. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105157 · Cited by 44
“We have reported that the globally active FAAH inhibitor, URB597 (Kathuria et al., 2003), reduced c-Fos expression in the trigeminal nucleus caudalis (TNC), NTG-induced hyperalgesia at the orofacial formalin test and expression of neuronal nitric oxide synthase, calcitonin gene-related peptide (CGRP) and cytokine gene…”
BackgroundSelf-citationZabik, N. L., Iadipaolo, A. S., Marusak, H. A., Peters, C., Burghardt, K. J., & Rabinak, C. A. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24860 · Cited by 48
“…AEA levels in key fear regions (e.g., basolateral amygdala) and prevents stress- induced anxiety- like behaviors and increases AEA levels (Bluett et al., 2014; Duan et al., 2017; Gunduz- Cinar, Hill, et al., 2013; Haller et al., 2009; Hill et al., 2013; Kathuria et al., 2003; Yasmin et al., 2020).”
BackgroundGreco, R., Demartini, C., Francavilla, M., Zanaboni, A. M., & Tassorelli, C. (2021) · Cells · doi:10.3390/cells10102543 · Cited by 46
“Both endocannabinoids and congeners can independently regulate pain sensation [6,67] via different and still undefined mechanisms, and the individual inhibition of their catabolic pathway has already proved beneficial in animal models specific for migraine [26,30].”
BackgroundMulder, A. M., & Cravatt, B. F. (2006) · Biochemistry · doi:10.1021/bi061122s · Cited by 45
Viveros, M., Marco, E. M., Llorente, R., & Lamota, L. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282d28fb4 · Cited by 46
“These results support a role for CB1–AEA system in the control of emotional behaviour and suggest an anxiolytic endocannabinoid tone (Kathuria et al., 2003).”
ResultGattinoni, S., Simone, C. D., Dallavalle, S., Fezza, F., Nannei, R., Amadio, D., Minetti, P., Quattrociocchi, G., Caprioli, A., Borsini, F., et al. (2010) · ChemMedChem · doi:10.1002/cmdc.200900472 · Cited by 44
Burston, J. J., Sim‐Selley, L. J., Harloe, J. P., Mahadevan, A., Razdan, R. K., Selley, D. E., & Wiley, J. L. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.141382 · Cited by 45
“To determine whether NAM selectively enhances the potency of 2-AG, G-protein activation by the endocannabinoid AEA was examined in mouse cerebellar membranes in the presence and absence of NAM or the established FAAH inhibitor URB597 (Kathuria et al., 2003).”
InfluentialDuan, T., Gu, N., Wang, Y., Wang, F., Zhu, J., Fang, Y., Shen, Y., Han, J., & Zhang, X. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160116 · Cited by 48
Dual Influence of Endocannabinoids on Long-Term Potentiation of Synaptic Transmission
Silva‐Cruz, A., Carlström, M., Ribeiro, J. A., & Sebastião, A. M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00921 · Cited by 46
“URB597 was used as a selective FAAH inhibitor at a concentration (1 µM) 200 times the IC50 to inhibit this enzyme (Kathuria et al., 2003).”
BackgroundMethodScherma, M., Fattore, L., Satta, V., Businco, F., Pigliacampo, B., Goldberg, S. R., Dessì, C., Fratta, W., & Fadda, P. (2012) · British Journal of Pharmacology · doi:10.1111/bph.12014 · Cited by 45
“3 and 3 mg·kg-1), FAAH inhibition was reported to be rapid (<15 min), persistent (>16 h) and correlated with a threefold increase in brain AEA levels (Kathuria et al., 2003; Fegley et al., 2005).”
BackgroundMethodInfluentialJohn, C. S., & Currie, P. J. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.05.025 · Cited by 46
The Multiple Pathways of Endocannabinoid Metabolism: A Zoom Out
Vandevoorde, S., & Lambert, D. M. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790156 · Cited by 51
Marrs, W., Horne, E. A., Ortega‐Gutiérrez, S., Cisneros, J. A., Xu, C., Lin, Y. H., Muccioli, G. G., López-Rodríguez, M. L., & Stella, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.202853 · Cited by 43
“In vivo FAAH inhibition recapitulates a narrow subset of the behavioral effects produced by CB1 agonists (7).”
InfluentialMangieri, R. A., Hong, K., Piomelli, D., & Sinha, R. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1518-3 · Cited by 48
“For example, blockade of anandamide deactivation by inhibition of the intracellular enzyme fattyacid amide hydrolase (FAAH; Kathuria et al. 2003) restores normal body-weight gain and sucrose intake in rats subjected to chronic mild stress (Bortolato et al.”
InfluentialSelf-citationLifelong Nutritional Omega-3 Deficiency Evokes Depressive-Like State Through Soluble Beta Amyloid
Morgese, M. G., Tucci, P., Mhillaj, E., Bové, M., Schiavone, S., Trabace, L., & Cuomo, V. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9809-2 · Cited by 47
“Endocannabinoids control mood and emotional phenotype and depressive and anxiety-like behaviors have been shown to be improved by increasing their levels [53, 54].”
BackgroundSelf-citationNew Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders
Scherma, M., Masia, P., Deidda, M. L., Fratta, W., Tanda, G., & Fadda, P. (2018) · Medicines · doi:10.3390/medicines5040107 · Cited by 48
The Endocannabinoid System: A New Molecular Target for the Treatment of Tobacco Addiction
Scherma, M., Fadda, P., Foll, B. L., Forget, B., Fratta, W., Goldberg, S. R., & Tanda, G. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708786927859 · Cited by 45
Nicotinic Facilitation of Δ9-Tetrahydrocannabinol Discrimination Involves Endogenous Anandamide
Solinas, M., Scherma, M., Tanda, G., Wertheim, C. E., Fratta, W., & Goldberg, S. R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.116830 · Cited by 44
Henricks, A. M., Berger, A. L., Lugo, J. M., Baxter-Potter, L. N., Bieniasz, K. V., Petrie, G. N., Sticht, M. A., Hill, M. N., & McLaughlin, R. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.023 · Cited by 50
Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats
Ho, W. ‐. V., & Gardiner, S. M. (2008) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00034.x · Cited by 43
“, 1996), and inhibition of FAAH can enhance and/or prolong the effects of anandamide in vivo (Kathuria et al., 2003; Batkai et al., 2004; Pacher et al., 2005b).”
BackgroundLozovaya, N., Min, R., Tsintsadze, V., & Burnashev, N. (2009) · Cell Calcium · doi:10.1016/j.ceca.2009.07.007 · Cited by 48
Lau, B. K., & Vaughan, C. W. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.045872 · Cited by 43
“…role in analgesia and anxiety in the PAG (Lichtman et al., 1996; Finn et al., 2003; Moreira et al., 2007), and modulation of the endocannabinoid system represents a promising new target for the treatment of anxiety and pain, particularly within the PAG (Kathuria et al., 2003; Hohmann et al., 2005).”
BackgroundEndocannabinoids: Getting the message across
Alger, B. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402935101 · Cited by 43
Basso, E., Duranti, A., Mor, M., Piomelli, D., Tontini, A., Tarzia, G., & Traldi, P. (2004) · Journal of Mass Spectrometry · doi:10.1002/jms.729 · Cited by 42
“2i 188 š 36 289 601 (35) 312 (100) 290 (50) 165 (5)”
Self-citationAlmeida-Santos, A. F., Gobira, P. H., Rosa, L. C., Guimaraes, F. S., Moreira, F. A., & Aguiar, D. C. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.05.027 · Cited by 41
Hill, M. N., Haney, M., Hillard, C. J., Karhson, D. S., & Vecchiarelli, H. A. (2023) · Psychological Medicine · doi:10.1017/s0033291723002465 · Cited by 44
“The development of FAAH inhibitors was one of the first pharmacological interventions developed for the eCB system, with the first FAAH inhibitor, URB597, being introduced almost 20 years ago (Kathuria et al., 2003).”
BackgroundComputational insights into function and inhibition of fatty acid amide hydrolase
Palermo, G., Röthlisberger, U., Cavalli, A., & Vivo, M. D. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.037 · Cited by 43
Dual Effect of Anandamide on Rat Placenta Nitric Oxide Synthesis
Cella, M., Leguizamón, G. F., Sordelli, M. S., Cervini, M., Guadagnoli, T., Ribeiro, M. L. C., Franchi, A. M., & Farina, M. (2008) · Placenta · doi:10.1016/j.placenta.2008.05.003 · Cited by 41
Cannabinoids, interoception, and anxiety
Andrade, A. K., Renda, B., & Murray, J. E. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.03.006 · Cited by 43
Bajaj, S., Jain, S., Vyas, P., Bawa, S., & Vohora, D. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.06.022 · Cited by 44
Lipophilic amines as potent inhibitors of N-acylethanolamine-hydrolyzing acid amidase
Yamano, Y., Tsuboi, K., Hozaki, Y., Takahashi, K., Jin, X., Ueda, N., & Wada, A. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.03.065 · Cited by 44
Conzelmann, A., Reif, A., Jacob, C., Weyers, P., Lesch, K., Lutz, B., & Pauli, P. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2785-y · Cited by 45
“…eCB signaling, respectively, are in accordance with the Hariri et al. (2009) findings (e.g., Basavarajappa et al. 2006; Bortolato et al. 2007; Kathuria et al. 2003; Mahler et al. 2007; Moreira et al. 2008; Pagotto et al. 2006; Solinas et al. 2007; Tanda and Goldberg 2003), some other studies…”
BackgroundResultInfluentialDe Chiara, V., Motta, C., Rossi, S., Studer, V., Barbieri, F., Lauro, D., Bernardi, G., & Centonze, D. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.06.069 · Cited by 37
Takahashi, E., Katayama, M., Niimi, K., & Itakura, C. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.05.020 · Cited by 41
Gamble‐George, J., Conger, J. R., Hartley, N. D., Gupta, P., Sumislawski, J. J., & Patel, S. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3042-8 · Cited by 41
Bambico, F. R., Duranti, A., Nóbrega, J. N., & Gobbi, G. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.12.027 · Cited by 44
“Likewise, amplifying the intrinsic level of anandamide by pharmacological (Kathuria et al., 2003, Gobbi et al., 2005, Realini et al., 2011; for review, Hillard and Liu, 2014; Gorzalka and Hill, 2011) or genetic (Bambico et al., 2010a, Cassano et al., 2010; for review, Hillard and Liu, 2014;…”
Self-citationWise, L. E., Shelton, C. C., Cravatt, B. F., Martin, B. R., & Lichtman, A. H. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.002 · Cited by 41
“Keywords: Cannabinoid CB1 receptor; FAAH [Fatty acid amide hydrolase]; N-arachidonoyl ethanolamine (anandamide); Pain; Analgesia; Marijuana”
BackgroundOpposing roles of mGluR8 in measures of anxiety involving non-social and social challenges
Duvoisin, R. M., Villasana, L., Davis, M. J., Winder, D. G., & Raber, J. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.02.049 · Cited by 40
Johnston, T. H., Huot, P., Fox, S. H., WAKEFIELD, J. D., Sykes, K. A., Bartolini, W. P., Milne, G. T., Pearson, J. P., & Brotchie, J. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.169532 · Cited by 44
“…FAAH inhibitors has previously been shown to inhibit brain FAAH enzyme activity in rodents and primates and to elevate AEA, N-oleoyl ethanolamide (OEA), and N-palmitoyl ethanolamide (PEA) in brain tissue (Kathuria et al., 2003; Lichtman et al., 2004; Justinova et al., 2008; Ahn et al., 2009).”
BackgroundEffects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats
Panlilio, L. V., Thorndike, E. B., Nikas, S. P., Alapafuja, S. O., Bandiera, T., Cravatt, B. F., Makriyannis, A., Piomelli, D., Goldberg, S. R., & Justinová, Z. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4140-6 · Cited by 42
“In preclinical testing, URB597 does not produce classical THC-like effects such as catalepsy, hypothermia, and hyperphagia (Kathuria et al. 2003).”
BackgroundSelf-citationCannabinoids in the Cardiovascular System
Ho, W. ‐. V., & Kelly, M. E. M. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.05.002 · Cited by 44
Applications of CBT-Cys click reaction: past, present, and future
Zhang, M., & Liang, G. (2018) · Science China Chemistry · doi:10.1007/s11426-018-9277-6 · Cited by 40
The endocannabinoid system in the amygdala and modulation of fear
Gunduz‐Cinar, O. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110116 · Cited by 45
Liu, Y., Lv, S., Peng, L., Xie, C., Gao, L., Sun, H., Lin, L., Ding, K., & Li, Z. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114636 · Cited by 42
Giuffrida, A., & McMahon, L. R. (2009) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2009.05.004 · Cited by 41
Metadata
- Authors
- Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., & Piomelli, D.
- Affiliations
- University of California, Irvine (US)
- University of Urbino (IT)
- University of Parma (IT)
- University of Naples Federico II (IT)
- University of Bari Aldo Moro (IT)
- Sapienza University of Rome (IT)
- Corresponding author
- Piomelli, Daniele
- ORCID
- Venue
- Nature Medicine
- Published
- 2002-12-02
- Volume
- 9
- Issue
- 1
- Pages
- 76-81
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4241363254
- Cited by
- 1,293
- References
- 45
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 25 · 2023: 35 · 2022: 34 · 2021: 32 · 2020: 48 · 2019: 45 · 2018: 35 · 2017: 45 · 2016: 59 · 2015: 76 · 2014: 66 · 2013: 72 · 2012: 70
- FWCI
- 29.07
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- anandamide, fatty acid amide hydrolase inhibition, anxiety, CB1 receptor, endocannabinoids, anxiolytics, benzodiazepine-like effects, elevated zero maze
- MeSH terms
- Rimonabant, Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Anxiety, Arachidonic Acids, Behavior, Animal, Cannabinoids, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Neurons, Piperidines, Pyrazoles, Radioligand Assay, Receptors, Drug, Anti-Anxiety Agents, Vocalization, Animal, Molecular Structure, Rats, Wistar, Receptors, Cannabinoid, Rats, Polyunsaturated Alkamides, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.